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Introduction {#sec005}
============

During the recent decades, the increasing aging population and the great gains in life expectancy have resulted in raised prevalence of neurodegenerative diseases including dementia. Globally, the number of people affected by dementia was almost 50 million in 2017 and is projected to increase to 131.5 million by 2050 \[[@pone.0236830.ref001]\]. In Australia, the number of people living with dementia was 447,115 in 2019. In the next four decades, the number will over double to reach an estimated number of 1,076,129 by 2058 \[[@pone.0236830.ref002]\].

Dementia is a term used to describe clinical syndromes associated with irreversibly progressive deterioration of multiple higher cortical functions, including language, memory, calculation, comprehension, thinking, learning skills and appropriate judgment, leading to interfering with functional ability and daily life \[[@pone.0236830.ref003],[@pone.0236830.ref004]\]. Due to the deterioration of cortical functions, especially in memory, people with dementia may take the medicine repeatedly or wrong medications, resulting in drug related problems (DRPs) and increased medication use. These problems have devastating effects on health outcomes, such as adverse drug events, morbidity and mortality. Dementia is the greatest risk factor of disability and premature mortality in Australian older people aged 65 years and older \[[@pone.0236830.ref005],[@pone.0236830.ref006]\]. In 2017, dementia was the second-leading cause of death in Australia, just after coronary artery diseases \[[@pone.0236830.ref007]\]. The average survival time of people living with dementia has ranged from 3 to 13 years \[[@pone.0236830.ref008],[@pone.0236830.ref009]\]. Finally, the economic impact of dementia has markedly been concerning. The estimated cost of dementia in Australia was over \$15 billion in 2019 and is estimated to increase to over \$36.8 billion by 2056 \[[@pone.0236830.ref006]\].

Dementia is usually associated with the development of three or more chronic diseases including hypertension, stroke, diabetes and coronary heart disease, resulting in increased health care needs and medication use \[[@pone.0236830.ref010]--[@pone.0236830.ref016]\]. Dementia and demented-related complications are common causes for unplanned visits to acute care sectors and then contribute to adverse consequences including falls, superimposed delirium, frailty, malnutrition, increased mortality rate and longer hospital stay \[[@pone.0236830.ref017]--[@pone.0236830.ref026]\]. In Australia, approximately 83,000 people with dementia are admitted to acute care settings each year \[[@pone.0236830.ref027]\]. In previous studies, between 15% to 40% of admitted patients were diagnosed with dementia, and they accounted for 10% of acute care bed days \[[@pone.0236830.ref028]--[@pone.0236830.ref032]\]. With regard to medication use, people with dementia are more likely to take many medications for treatment of cognitive problems, psycho-behavioral symptoms and multiple comorbidities, compared with people without dementia \[[@pone.0236830.ref033],[@pone.0236830.ref034]\]. Most geriatric patients with dementia usually consume a mean of five or more medications, commonly defined as polypharmacy (PP) \[[@pone.0236830.ref035]--[@pone.0236830.ref039]\]. Although taking multiple medications may be necessary for the management of dementia and chronic diseases, the use of multiple medications can lead to greater risk of DRPs, including potentially inappropriate medications (PIMs), drug-drug interactions (DDIs), and adverse drug reactions (ADRs) \[[@pone.0236830.ref040]--[@pone.0236830.ref045]\]. Apart from polypharmacy, age-related pharmacokinetic and pharmacodynamic changes can pose higher risk for undesirable DRPs \[[@pone.0236830.ref046],[@pone.0236830.ref047]\]. Furthermore, older people with dementia have an alteration of blood-brain permeability and levels of endogenous neurotransmitters which may increase their sensitivity to neurological effects of medications, leading to greater experience of ADRs \[[@pone.0236830.ref046],[@pone.0236830.ref048],[@pone.0236830.ref049]\]. The PP and DRPs result in an increased risk of hospital admission, morbidity, mortality and health care burdens \[[@pone.0236830.ref050]--[@pone.0236830.ref053]\]. These problems tend to occur more frequently and are more serious in geriatric population with dementia due to their vulnerability than in younger population. The exposure to the combination of PP and DRPs is commonly identified in older patients with dementia. Many previous studies have reported high prevalence of PP and DRPs among older patients with dementia admitted to hospitals. Studies have reported the exposure of 82--98% of this vulnerable population to the PP \[[@pone.0236830.ref054]--[@pone.0236830.ref056]\], 22.4--96% to the PIM \[[@pone.0236830.ref056]--[@pone.0236830.ref059]\] and 43.2% to the DDI \[[@pone.0236830.ref060]\].

However, although many studies have assessed aspects related to PP, PIM or DDI, no previous study has explored prevalence and associated risk factors for the exposure to three criteria or triad combination of PP, PIM and DDI among the older people with dementia admitted in acute care setting.

The first aim of the current study was to evaluate risk factors associated with the exposure to triad combination of PP, PIM and DDI among patients with dementia. The other aim was to assess prevalence and characteristics of PP, PIM and DDI and to determine the most frequently implicated medications in the context of this vulnerable population.

Materials and methods {#sec006}
=====================

Study design, setting and participants {#sec007}
--------------------------------------

The present study was a secondary analysis of data from the Comprehensive electronic Geriatric Assessment database \[[@pone.0236830.ref061]\] of patients referred for specialist geriatric consultation at Princess Alexandra Hospital, Brisbane, Australia during the period from January 1, 2006 to December 31, 2016. The interRAI Acute Care (AC) tool was used for comprehensive geriatric assessment \[[@pone.0236830.ref062]\]. The criteria for selection of individuals into the study were patients aged 65 years and over with dementia based on the medical records of disease diagnosis "dementia" combined with cognitive performance scale (CPS) scores ranging from 2 to 6, derived from the interRAI Acute Care assessment. The participants were categorized into two groups: triad combination group and non-triad combination group. The triad combination group comprised those patients exposed to all three criteria of PP, PIM and DDI. The non-triad combination group comprised those without exposure to the combination of three criteria of PP, PIM and DDI.

Data collection and measurement tools {#sec008}
-------------------------------------

In this study, all data were de-identified health data provided from the interRAI Acute Care (AC) database \[[@pone.0236830.ref062],[@pone.0236830.ref063]\]. A standardized interRAI Acute Care (AC) assessment tool was used to support comprehensive geriatric assessment (CGA) in the acute setting for the older patients \[[@pone.0236830.ref061]\] at admission, trained nurse assessors gathered comprehensive health information data including physical, physiological-behavioral and socio-economic status, and conducted many clinical assessments for example, cognitive status, psycho-behavioural conditions and activities of daily living. If patients were not able to provide the medical information, a relative or a proxy informant could offer the required information. The individual variables (covariates) included baseline characteristics, living situation, primary diagnosis, comorbidities, geriatric syndrome, activity of daily living (ADL), instrumental activity of daily living (IADL), moods and behavioral patterns, cognitive functions, service utilization and all prescribed medications \[[@pone.0236830.ref062]\]. Within 24 hours of admission, trained nurse assessors gathered and recorded all health data and lists of prescribed medications. The participant' s cognitive function was evaluated by embedded computer algorithms of InterRAI Acute Care (AC), which interpreted collected clinical data such as moods, behavior, and cognitive functions to create a CPS, correlated with Mini-Mental State Examination (MMSE), with scores ranging from 0 (intact cognition) to 6 (very severe cognitive impairment) \[[@pone.0236830.ref064]\]. Functional capacity and levels of dependence were evaluated by short ADL scale at admission and premorbid IADLs scale which were also embedded in InterRAI Acute Care (AC) database \[[@pone.0236830.ref063],[@pone.0236830.ref065]\]. The ADL short-form scale at admission evaluates obtained assistance in performing four activities including eating, personal hygiene, toilet use and walking, ranging from 0 to 16 with higher scores indicating greater level of incapacity \[[@pone.0236830.ref063],[@pone.0236830.ref066]\]. Premorbid IADL scale summarized the performance on seven IADL items (housework, meal preparation, shopping, finances, transport, phone use and medication management). Performance scores for each item range from 0 (independent) to 6 (total dependence). The summed scores were analysed to generate a scale ranging from 0 to 42, with higher scores indicating a greater level of dependence \[[@pone.0236830.ref063],[@pone.0236830.ref066]\]. With regard to medication data, the medication name, frequency, route of administration and doses were recorded in the databases. All recorded medications were classified by Anatomical Therapeutic Chemical (ATC) codes \[[@pone.0236830.ref067]\], following recommendation by the World Health Organization, as the international standard to present medication usage data. Finally, the prevalence and characteristics of PP, PIM and DDI were determined by a geriatrician and/or pharmacist using following definitions.

Definitions {#sec009}
-----------

### Drug-Related Problem (DRP) {#sec010}

DRP is defined as any undesirable circumstance involving medication therapy which potentially interferes with desired health consequences \[[@pone.0236830.ref068]\]. In the current study, DRPs consist of presence of PIM and DDI.

### Polypharmacy (PP) {#sec011}

PP is defined as the simultaneous consumption of five or more prescribed medications, based upon the number of regular prescribed medications documented in the InterRAI Acute Care (AC) database \[[@pone.0236830.ref069]\].

### Potentially Inappropriate Medication (PIM) {#sec012}

By definition, PIM is a medication that should be avoided in an individual due to the health risks outweighing the clinical benefits \[[@pone.0236830.ref070]\]. In this study, PIMs were determined using the 2019 American Geriatrics Society (AGS) Beers Criteria^®^ (AGS Beers Criteria^®^), which are the fifth updated of the AGS Beers Criteria^®^ \[[@pone.0236830.ref071]\]. In the present study, PIMs independent of medical condition and PIMs that should be avoided in the older adults due to drug-disease or drug-syndrome interactions were determined.

### Drug-Drug Interaction (DDI) {#sec013}

The definition of DDI is a situation in which one substance affects the activity of another drug when both are used simultaneously, regardless whether adverse events will occur or not \[[@pone.0236830.ref072]\]. All prescribed medications were analyzed by Micromedex Drug Interaction Database \[[@pone.0236830.ref073]\] to determine drug interactions which were considered only single pairwise of drug combination. In this study, potential drug interactions were reported in terms of severity and interaction effect. With respect to severity rating risk, DDIs were categorized into four classifications: minor, moderate, major and contraindicated DDIs \[[@pone.0236830.ref073]\]. Only the risk of potential adverse outcomes related to drug interactions were explored, but clinical relevant outcomes were not included.

Statistical analysis {#sec014}
--------------------

Statistical analyses were performed using the SPSS for Windows Software Package, Version 25 (SPSS Inc., Chicago, Ill., USA). To describe population characteristics and medication profiles, the percentage was used for categorical variables and mean ± standard deviation (SD) or median ± interquartile range (IQR) was used for continuous variables. Pearson's chi-squared test or Fisher's exact for categorical variables and Unpaired Student's t-test or Mann-Whitney U test for continuous variables were performed to compare baseline characteristics, physical and cognitive function, medication profiles between triad combination group and non-triad combination group. Univariate logistic regression analysis was used first to evaluate the effect of variables on the exposure to triad combination of PP, PIM and DDI. Factors determined as significant variables from univariate logistic analysis (significance set at p\<0.05 level), age, gender, number of comorbidity, short ADL scale at admission and premorbid IADLs were included in the final multivariate logistic regression analysis to estimate independent risk factors associated with the exposure to triad combination of PP, PIM and DDI. Additionally, subgroup analyses were performed to evaluate risk factors associated with greater exposure to each criterion of PP, PIM and DDI using bivariate and multivariate logistic regression analyses. The results from logistic regression analyses were presented as odd ratios (ORs) and 95% confidence intervals (CIs). Statistical significance levels for variables were determined at the level of p\<0.05.

The present study was a secondary retrospective cross-sectional analysis of de-identified data provided by the interRAI Acute Care (AC) assessment database. The researchers did not require to identify the data and to contact the participants. Exemption from ethics approval was obtained from the Metro South Human Research Ethics Committee and Human Research.

Results {#sec015}
=======

Baseline and clinical characteristics {#sec016}
-------------------------------------

Of 2,992 older patients age 65 years and older referred for geriatric consultation services at Princess Alexandra Hospital from 2006 to 2016, a total of 416 older patients with dementia (13.9%) were enrolled. The eligible participants were categorized into two groups: triad combination group and non-triad combination group. Overall, 181 (43.5%) participants and 235 (56.5%) participants were classified as triad combination group and non-triad combination group respectively. The descriptive analysis and a comparison of population study in terms of baseline and clinical characteristics between the two groups are presented in [Table 1](#pone.0236830.t001){ref-type="table"}.

10.1371/journal.pone.0236830.t001

###### Demographic and clinical characteristics of the population.

![](pone.0236830.t001){#pone.0236830.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                                    Triad combination (n = 181) N (%)   Non-triad combination (n = 235) N (%)   *P* value
  ---------------------------------------------------------------------------------- ----------------------------------- --------------------------------------- ----------------------------------------------
  Age in years, mean (SD)                                                            82.5 (7.0)                          82.7 (7.2)                              0.791[^\#^](#t001fn003){ref-type="table-fn"}

  65--75 years                                                                       33 (18.2)                           44 (18.7)                               

  \> 75 years                                                                        148 (81.8)                          191 (81.3)                              

  **Sex**                                                                                                                                                        

      Male                                                                           89 (49.2)                           103 (43.8)                              0.279[\*](#t001fn002){ref-type="table-fn"}\

      Female                                                                         92 (50.8)                           132 (56.2)                              

  **Marital status**                                                                                                                                             

      Single                                                                         8 (4.4)                             12 (5.1)                                0.289[\*](#t001fn002){ref-type="table-fn"}

      Married                                                                        76 (42.0)                           78 (33.2)                               

      Widowed                                                                        73 (40.3)                           114 (48.5)                              

      Divorced or separated                                                          24 (13.3)                           31 (13.2)                               

  Living alone                                                                       55 (30.4)                           95 (40.4)                               0.035[\*](#t001fn002){ref-type="table-fn"}

  **Admission sources**                                                                                                                                          

      Community                                                                      152 (84.0)                          213 (90.6)                              0.059[\*](#t001fn002){ref-type="table-fn"}

      Hospital                                                                       4 (2.2)                             6 (2.6)                                 

      RACF                                                                           25 (13.8)                           16 (6.8)                                

  Length of hospital stay in days, median (IQR)                                      32 (22, 50.5)                       31 (21, 44)                             0.408[^+^](#t001fn003){ref-type="table-fn"}

  **Discharge destination**                                                                                                                                      

      Community                                                                      75 (41.4)                           92 (39.1)                               0.640[\*](#t001fn002){ref-type="table-fn"}

      Hospital                                                                       23 (12.7)                           24 (10.2)                               

      RACF                                                                           74 (40.9)                           102 (43.4)                              

      Death                                                                          9 (5.0)                             17 (7.2)                                

  **Comorbidities**                                                                                                                                              

      No. of comorbidities/person, mean (SD)                                         5.8 (1.9)                           5.2 (2.0)                               0.001[^\#^](#t001fn003){ref-type="table-fn"}

      No. of comorbidities \> 3/ person                                              156 (86.2)                          187 (79.6)                              0.079[\*](#t001fn002){ref-type="table-fn"}

      Hypertension                                                                   93 (51.4)                           120 (51.1)                              0.949[\*](#t001fn002){ref-type="table-fn"}

      Diabetes mellitus                                                              46 (25.4)                           36 (15.3)                               0.010[\*](#t001fn002){ref-type="table-fn"}

      Coronary artery disease                                                        65 (35.9)                           62 (26.4)                               0.036[\*](#t001fn002){ref-type="table-fn"}

      Atrial fibrillation                                                            47 (26.0)                           34 (14.5)                               0.003[\*](#t001fn002){ref-type="table-fn"}

      Ischemic stroke                                                                37 (20.4)                           39 (16.6)                               0.314[\*](#t001fn002){ref-type="table-fn"}

      Dyslipidemia                                                                   50 (27.6)                           53 (22.6)                               0.235[\*](#t001fn002){ref-type="table-fn"}

      Malignancy                                                                     39 (21.5)                           48 (20.4)                               0.780[\*](#t001fn002){ref-type="table-fn"}

      Infection                                                                      71 (39.2)                           86 (36.6)                               0.583[\*](#t001fn002){ref-type="table-fn"}

      GERD                                                                           57 (31.5)                           56 (23.8)                               0.082[\*](#t001fn002){ref-type="table-fn"}

      Osteoporosis                                                                   36 (19.9)                           29 (12.3)                               0.036[\*](#t001fn002){ref-type="table-fn"}

      Delirium                                                                       35 (10.5)                           17 (7.2)                                0.241[\*](#t001fn002){ref-type="table-fn"}

  **Primary diagnosis**                                                                                                                                          

      Dementia with psycho-behavioral symptoms                                       54 (29.8)                           70 (29.8)                               1.000[\*](#t001fn002){ref-type="table-fn"}

      Fall                                                                           44 (24.3)                           51 (21.7)                               0.560[\*](#t001fn002){ref-type="table-fn"}

      Urinary tract infection                                                        32 (17.7)                           32 (13.6)                               0.476[\*](#t001fn002){ref-type="table-fn"}

  Weight (kg), median (IQR)                                                          60 (52, 73)                         60 (52, 70)                             0.884[^+^](#t001fn003){ref-type="table-fn"}

  BMI (kg/m^2^), mean (SD)                                                           23.4 (4.5)                          22.8 (4.5)                              0.167[^\#^](#t001fn003){ref-type="table-fn"}

  **Geriatric syndrome**                                                                                                                                         

  Cognitive status at admission[^a^](#t001fn006){ref-type="table-fn"}                                                                                            

      Mild-moderate impairment (2--4)                                                141 (77.9)                          187 (79.6)                              0.698[\*](#t001fn002){ref-type="table-fn"}

      Severe impairment (5--6)                                                       40 (22.1)                           48 (20.4)                               

  Short ADL scale at admission, median (IQR)[^b^](#t001fn007){ref-type="table-fn"}   6 (3.5, 11)                         7 (2, 10)                               0.130[^+^](#t001fn003){ref-type="table-fn"}

  Premorbid IADLs, mean (SD)[^c^](#t001fn008){ref-type="table-fn"}                   31.8 (11.2)                         29.3 (12.8)                             0.032[^\#^](#t001fn003){ref-type="table-fn"}

  Weight loss[^d^](#t001fn009){ref-type="table-fn"}                                  37 (20.4)                           56 (23.8)                               0.411[\*](#t001fn002){ref-type="table-fn"}

  Urinary incontinence                                                               122 (67.4)                          150 (63.8)                              0.448[\*](#t001fn002){ref-type="table-fn"}

  Visual problems                                                                    84 (46.4)                           89 (37.9)                               0.080[\*](#t001fn002){ref-type="table-fn"}

  Auditory problems                                                                  94 (51.9)                           111 (47.2)                              0.342[\*](#t001fn002){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Data are presented as** mean (standard deviation), n (%), or median (interquartile range).

\* Chi-square test

^\#^ Student's t-test

^+^ Mann--Whitney U test.

**Abbreviations:** RACF, residential aged care facilities; SD, standard deviation; IQR, interquartile range; GERD, gastroesophageal reflux disease; kg, kilogram; m, meter; BMI, body mass index; ADL, activities of daily living; IADL, instrumental ADL.

^a^ Based on the CPS, which ranges from 0 (intact cognition) to 6 (very severe cognitive impairment); \[[@pone.0236830.ref064]\] cognitively impaired patients were defined as CPS scores ≥ 2, corresponding to a mean Mini Mental State Examination score of \< 24 \[[@pone.0236830.ref064]\]

^b^The ADL short-form scale comprises four items (personal hygiene, walking, toilet use and eating); range is 0--16, with higher scores reflecting greater level of dependency \[[@pone.0236830.ref063],[@pone.0236830.ref066]\].

^c^ Premorbid IADL scale summarizes the performance on seven IADL items (meal preparation, housework, finances, medication management, phone use, shopping, and transport). The scale has a range from 0 to 42, with higher scores indicating greater dependence \[[@pone.0236830.ref063],[@pone.0236830.ref066]\].

^d^ Loss of ≥ 5% bodyweight in the 30 days before admission or ≥ 10% in the 180 days before admission.

The majority of the participants were female (n = 224; 53.8%). The age ranged from 65 to 101 years with mean of 82.3 years (SD 7.1 years), which was not significantly different between the two groups. Over half of the participants were widowed, divorced or separated. The majority of the total population (\> 80%) resided in their own homes, but less than half of them lived alone. In the current study, it was found that the number of the patients lived alone in triad combination group was significantly lower as compared to the non-triad combination group. Approximately one tenth were admitted from residential aged care facilities. The median length of hospital admission was not significantly different between the two groups (p = 0.408). With regard to discharge destination, over 40% were discharged to RACF. In both groups, approximately 6% ended their lives in hospital. Dementia with psycho-behavioural symptoms (29.8%), falls (22.8%) and urinary tract infection (15.4%) were the main causes of the current hospitalization. The participants in the triad combination group had substantially more comorbidities as compared to the non-triad combination group (p = 0.001). More than three quarters of the total population had three or more comorbidities. In both groups, the participants were more likely to have hypertension, infection and coronary artery disease. It was found that the number of participants having diabetes, coronary artery disease, atrial fibrillation and osteoporosis in the triad combination were markedly higher comparing with the non-triad combination group (p\<0.05). With respect to functional capacity and geriatric syndrome, the majority of the participants were more likely to have impaired hearing (49.3%), urinary incontinence (65.4%), and mild to moderate cognitive impairment (78.8%) with CPS scores ranging from 2 to 4. The participants in the triad combination group had a tendency to be of greater dependence in IADL as compared to those in the non-triad combination group \[31.8 (SD 11.2) in the triad combination group vs 29.3 (SD 12.8) in the non-triad combination group, p = 0.032\].

Medication use {#sec017}
--------------

The most common prescribed medications categorized by ATC codes are presented in [Table 2](#pone.0236830.t002){ref-type="table"}. The total number of regular prescribed medications was 3,027. The number of regular prescribed medications per person ranged from 0 to 19. Two participants in the non-triad combination group and six in the triad combination group consumed more than 15 medications. The median number of prescribed medications was 8 (IQR 6--10 medications) in the triad combination group and 6 (IQR 4--8 medications) in the non-triad combination group. This was significantly different between the two groups (p\< 0.001). Three most frequently prescribed medication categories were antithrombotic agents (76.4%), followed by drugs for constipation (41.8%) and agent acting on the renin-angiotensin system (39.4%). In the triad combination group, prescriptions of cardiac therapy, diuretics, psycholeptics and psychoanaleptics were substantially higher as compared to the non-triad combination group (p\<0.001). Up to 10% of the total participants were using anti-dementia medications which consisted of three cholinesterase inhibitors and one N-methyl-D-aspartate (NMDA) receptor antagonists.

10.1371/journal.pone.0236830.t002

###### Prescribed medications use of the population according to ATC system.

![](pone.0236830.t002){#pone.0236830.t002g}

  Characteristics                                                 Triad combination (n = 181) N (%)   Non-triad combination (n = 235) N (%)   *P* value
  --------------------------------------------------------------- ----------------------------------- --------------------------------------- -----------------------------------------------
  Total number of medications                                     1577 (100)                          1450 (100)                              
  No. of prescribed medications/person, median (IQR)              8 (6, 10)                           6 (4, 8)                                \<0.001[^+^](#t002fn003){ref-type="table-fn"}
  **Prescribed medications according to ATC classes and codes**                                                                               
  A02 Drugs for acid related disorders                            70 (38.7)                           65 (27.7)                               0.017[\*](#t002fn002){ref-type="table-fn"}
  A06 Drugs for constipation                                      77 (42.5)                           97 (41.3)                               0.795[\*](#t002fn002){ref-type="table-fn"}
  A10 Drug used in diabetes                                       34 (18.8)                           24 (10.2)                               0.012[\*](#t002fn002){ref-type="table-fn"}
  A11 Vitamins                                                    69 (38.1)                           87 (37.0)                               0.818[\*](#t002fn002){ref-type="table-fn"}
  A12 Mineral supplements                                         75 (41.4)                           68 (28.9)                               0.008[\*](#t002fn002){ref-type="table-fn"}
  B01 Antithrombotic agents                                       144 (79.6)                          174 (74.0)                              0.189[\*](#t002fn002){ref-type="table-fn"}
  C01 Cardiac therapy                                             51 (28.2)                           21 (8.9)                                \< 0.001[\*](#t002fn002){ref-type="table-fn"}
  C02 Antihypertensives                                           11 (6.1)                            5 (2.1)                                 0.038[\*](#t002fn002){ref-type="table-fn"}
  C03 Diuretics                                                   54 (29.8)                           35 (14.9)                               \<0.001[\*](#t002fn002){ref-type="table-fn"}
  C07 Beta blocking agents                                        66 (36.5)                           62 (26.4)                               0.027[\*](#t002fn002){ref-type="table-fn"}
  C08 Calcium channel blockers                                    32 (17.7)                           42 (17.9)                               0.959[\*](#t002fn002){ref-type="table-fn"}
  C09 Agents acting on the renin- angiotensin system              84 (46.4)                           80 (34.0)                               0.011[\*](#t002fn002){ref-type="table-fn"}
  C10 Lipid modifying agents                                      76 (42.0)                           70 (29.8)                               0.010[\*](#t002fn002){ref-type="table-fn"}
  D Dermatologicals                                               6 (3.3)                             13 (9.3)                                0.035[\*](#t002fn002){ref-type="table-fn"}
  H02 Corticosteroids                                             15 (8.3)                            18 (7.7)                                0.060[\*](#t002fn002){ref-type="table-fn"}
  **Prescribed medications according to ATC classes and codes**                                                                               
  H03 Thyroid therapy                                             29 (16.0)                           21 (8.9)                                0.028[\*](#t002fn002){ref-type="table-fn"}
  J01 Antibacterial drugs                                         44 (24.3)                           44 (18.7)                               0.167[\*](#t002fn002){ref-type="table-fn"}
  N02 Analgesics                                                  77 (42.5)                           80 (34.0)                               0.076[\*](#t002fn002){ref-type="table-fn"}
  N03 Antiepileptics                                              19 (10.5)                           10 (4.3)                                0.013[\*](#t002fn002){ref-type="table-fn"}
  N05 Psycholeptics                                               97 (53.6)                           45 (19.1)                               \< 0.001[\*](#t002fn002){ref-type="table-fn"}
      N05A Antipsychotics                                         82 (45.3)                           37 (15.7)                               \< 0.001[\*](#t002fn002){ref-type="table-fn"}
      N05B-N05C Anxiolytics, sedatives and hypnotics              31 (17.1)                           12 (5.1)                                \< 0.001[\*](#t002fn002){ref-type="table-fn"}
  N06 Psychoanaleptics                                            74 (40.9)                           49 (20.9)                               \< 0.001[\*](#t002fn002){ref-type="table-fn"}
      N06A Antidepressants                                        65 (35.9)                           37 (15.7)                               \< 0.001[\*](#t002fn002){ref-type="table-fn"}
      N06D Anti-dementia drugs                                    20 (11.0)                           16 (6.8)                                0.127[\*](#t002fn002){ref-type="table-fn"}
  R03 Drugs for obstructive airway diseases                       19 (10.5)                           22 (9.4)                                0.700[\*](#t002fn002){ref-type="table-fn"}

**Data are presented as** n (%), or median (interquartile range).

\* Chi-square test

^+^ Mann--Whitney U test.

**Abbreviations:** IQR, interquartile range; ATC, anatomical therapeutic chemical.

PP, PIM and DDI {#sec018}
---------------

In both groups, approximately 78% of the participants were exposed to PP. Approximately 76% of the participants experienced at least 1 potential DDI, and 233 participants (56%) had at least 1 PIM, as shown in [Table 3](#pone.0236830.t003){ref-type="table"}.

10.1371/journal.pone.0236830.t003

###### Prevalence of medication issues in the study population.

![](pone.0236830.t003){#pone.0236830.t003g}

  Characteristics                                                                          N (%)
  ---------------------------------------------------------------------------------------- ------------
  **Number of participants with the different combinations of criteria of PP, PIM, DDI**   416 (100)
      None                                                                                 43 (10.3)
      Only PP                                                                              20 (4.8)
      Only PIM                                                                             23 (5.5)
      Only DDI                                                                             7 (1.7)
      PP + PIM                                                                             14 (3.4)
      PP + DDI                                                                             112 (26.9)
      PIM + DDI                                                                            16 (3.8)
      PP + PIM + DDI                                                                       181 (43.5)
  **Potentially inappropriate medications (PIMs), elderly person**                         416 (100)
      0                                                                                    183 (44.0)
      1                                                                                    141 (33.9)
      2                                                                                    65 (15.6)
      3                                                                                    23 (5.5)
      4                                                                                    4 (1.0)
  **Drug-drug interactions (DDIs), elderly person**                                        416 (100)
      Without DDI                                                                          100 (24.0)
      With 1--5 DDIs                                                                       230 (55.3)
      With 6--10 DDIs                                                                      63 (15.1)
      With \> 10 DDIs                                                                      23 (5.5)
  **Drug-drug interactions (DDIs)**                                                        1360 (100)
      Contraindicated DDI                                                                  3 (0.2)
      Major DDI                                                                            672 (49.4)
      Moderate DDI                                                                         621 (45.7)
      Minor DDI                                                                            64 (4.7)

**Data are presented as** n (%).

**Abbreviations:** PP, polypharmacy; PIM, potentially inappropriate medication; DDI, drug-drug interaction.

Four participants (1%) were on 4 PIMs. With regard to DDI, 23 participants (5.5%) were exposed to \> 10 potential DDIs. Overall, 373 participants (89.7%) were exposed to at least 1 criteria of PP, PIM and/or DDI. Of these 373, 50 (12%) were exposed to one criterion, 142 (34.1%) to two criteria, and 181 (43.5%) to all three criteria.

A total of 657 PIMs were identified among the study population, as presented in [Table 4](#pone.0236830.t004){ref-type="table"}. The most common prescribed PIM were for neurological and cardiovascular systems. Antipsychotics and benzodiazepines were the most frequently prescribed PIMs.

10.1371/journal.pone.0236830.t004

###### Potentially inappropriate medications of the population study according to the 2019 Beers Criteria.
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  PIMs Independent of Medical Condition     PIMs due to Drug-Disease or Drug-Syndrome Interactions                                             
  ----------------------------------------- -------------------------------------------------------- ----------------------------------------- ------------
  **According to systems**                  **According to systems**                                                                           
  Central nervous system                    210 (37.7)                                               Cardiovascular system                     2 (0.4)
  Cardiovascular system                     60 (10.8)                                                Syncope                                   2 (0.4)
  Endocrine                                 7 (1.3)                                                  Central nervous system                    245 (44.0)
  Pain medications                          5 (0.9)                                                  Delirium                                  60 (10.8)
  **According to therapeutic categories**   Dementia or cognitive impairment                         185 (33.2)                                
  Peripheral alpha-1 blockers               16 (2.9)                                                 History of falls or fractures             121 (21.7)
  Antiarrhythmic agents                     44 (7.9)                                                 Gastrointestinal system                   3 (0.5)
  Barbiturates                              1 (0.2)                                                  Parkinson disease                         4 (0.7)
  Benzodiazepines                           58 (10.4)                                                **According to therapeutic categories**   
  Antipsychotics                            119 (21.4)                                               AChEIs                                    2 (0.4)
  Antidepressants                           23 (4.1)                                                 Antipsychotics                            213 (38.2)
  Other CNS alpha-agonists                  1 (0.2)                                                  Benzodiazepines                           94 (16.9)
  Anticholinergics                          8 (1.4)                                                  Anticholinergics                          13 (2.3)
  Estrogen                                  6 (1.1)                                                  Corticosteriods                           4 (0.8)
  Sulfonylureas, long acting                1 (0.2)                                                  Antiepileptics                            10 (1.8)
  Non-COX-2-selective NSAIDs                5 (0.9)                                                  Antidepressants                           35 (6.3)
  **Total**                                 282 (42.9)                                               Tramadol                                  1 (0.2)
                                                                                                     Non-COX-2-selective NSAIDs                3 (0.5)
                                                                                                     **Total**                                 375 (57.1)

**Data are presented as** n (%).

**Abbreviation:** PIMs, Potentially inappropriate medications; AChEIs, Acetylcholinesterase inhibitors; CNS, central nervous system; Non-COX-2-selective NSAIDs, Non-cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs.

In the current study, 1360 medication combinations resulted in potential DDIs, as shown in Tables [3](#pone.0236830.t003){ref-type="table"} and [5](#pone.0236830.t005){ref-type="table"}. The majority of the participants (49.4%) were exposed to major DDIs. Three single pairwise of drug combinations contributed to contraindicated DDIs, for example, the combination of haloperidol with metoclopramide, citalopram with metoclopramide and oxybutynin with potassium. The drug combination frequently implicated in potential DDI was that of heparin with aspirin, the interactive effect of which increases the risk of bleeding.

10.1371/journal.pone.0236830.t005

###### Lists of contraindicated drug interactions and most common major drug interactions with potential effects according to Micromedex Drug Interaction Database.
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  Drug combination                        Potential effects                                                                                  (n = 1360) N (%)
  --------------------------------------- -------------------------------------------------------------------------------------------------- ------------------
  **Contraindicated drug interactions**                                                                                                      
  Haloperidol + Metoclopramide            Increased risk of extrapyramidal reaction and neuroleptic malignant syndrome                       1 (0.1)
  Citalopram + Metoclopramide             Increased risk of extrapyramidal reaction and neuroleptic malignant syndrome                       1 (0.1)
  Oxybutynin + Potassium                  Increased risk of gastrointestinal lesions                                                         1 (0.1)
  **Major drug interactions**                                                                                                                
  Heparin + Aspirin                       Increased risk of bleeding                                                                         82 (6.0)
  Aspirin + Furosemide                    Reduced diuretic effectiveness and possible nephrotoxicity                                         52 (3.8)
  Polyethylene glycol + Senna             Increased risk of mucosal ulceration or ischemic colitis                                           39 (2.9)
  Aspirin + Metformin                     Increased risk of hypoglycemia                                                                     20 (1.5)
  Aspirin + Digoxin                       Increased serum concentration of digoxin; prolonged half-life of digoxin                           17 (1.3)
  Clopidogrel + Heparin                   Increased risk of bleeding                                                                         14 (1.0)
  Sertraline + Aspirin                    Increased risk of bleeding                                                                         12 (0.9)
  Citalopram + Aspirin                    Increased risk of bleeding                                                                         12 (0.9)
  Citalopram + Heparin                    Increased risk of bleeding                                                                         12 (0.9)
  Clopidogrel + Omeprazole                Reduced plasma concentrations of clopidogrel active metabolite and reduced antiplatelet activity   12 (0.9)

**Data are presented as** n (%).

Factors associated with the exposure to triad combination {#sec019}
---------------------------------------------------------

After univariate logistic regression analyses were performed, significant variables for the exposure to all three criteria of PP, PIM and DDI were identified, as shown in [Table 6](#pone.0236830.t006){ref-type="table"}. These significant variables, age, sex, number of comorbidities, short ADL at admission, premorbid IADL were added to adjust multivariate logistic model. After this adjustment, the independent risk factors of triad combination were the presence of diagnosis of atrial fibrillation (OR = 2.12 \[1.93--3.96\]) and increased medication use in cardiac therapy (OR = 3.49 \[1.76--6.92\]), psycholeptics (OR = 7.09 \[4.23--11.87\]) and psychoanaleptics (OR = 2.41 \[1.44--4.03\]). However, the degree of cognitive impairment, age, sex, ADLs and number of comorbidities were not associated factors for the exposure to triad combination of PP, PIM and DDI.

10.1371/journal.pone.0236830.t006

###### Logistic regression model of factors associated with exposure to triad combination of PP, PIM and DDI.
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  Variables                                            Unadjusted OR (95%CI)   *P*- value   Adjusted OR[^a^](#t006fn001){ref-type="table-fn"} (95%CI)   *P*- value
  ---------------------------------------------------- ----------------------- ------------ ----------------------------------------------------------- ------------
  **Patient characteristics**                                                                                                                           
  Age                                                  0.99 (0.97--1.02)       0.790                                                                    
  Female                                               0.81 (0.55--1.19)       0.279                                                                    
  Short ADL scale                                      1.03 (0.99--1.07)       0.170                                                                    
  Premorbid IADLs                                      1.02 (1.00--1.04)       0.036                                                                    
  Number of comorbidities                              1.19 (1.07--1.31)       0.001                                                                    
  Diabetes mellitus                                    1.88 (1.16--3.07)       0.011                                                                    
  Coronary artery disease                              1.56 (1.03--2.38)       0.037                                                                    
  Atrial fibrillation                                  2.07 (1.27--3.39)       0.004        2.12 (1.93--3.96)                                           0.019
  Osteoporosis                                         1.76 (1.04--3.01)       0.037                                                                    
  **Medications characteristics**                                                                                                                       
  A02 Drugs for acid related disorders                 1.65 (1.09--2.49)       0.018                                                                    
  A10 Drug used in diabetes                            2.03 (1.16--3.57)       0.014                                                                    
  A12 Mineral supplements                              1.74 (1.16--2.62)       0.008                                                                    
  C01 Cardiac therapy                                  3.99 (2.30--6.95)       \<0.001      3.49 (1.76--6.92)                                           \<0.001
  C03 Diuretics                                        2.43 (1.50--3.93)       \<0.001                                                                  
  C09 Agents acting on the renin- angiotensin system   1.68 (1.13--2.49)       0.011                                                                    
  C10 Lipid modifying agents                           1.71 (1.14--2.56)       0.010                                                                    
  H03 Thyroid therapy                                  1.94 (1.07--3.54)       0.030                                                                    
  N03 Antiepileptics                                   2.64 (1.19--5.83)       0.016                                                                    
  N05 Psycholeptics                                    4.88 (3.15--7.55)       \<0.001      7.09 (4.23--11.87)                                          \<0.001
  N06 Psychoanaleptics                                 2.63 (1.70--4.05)       \<0.001      2.41 (1.44--4.03)                                           0.001

^a^ Adjusted for age, sex, number of comorbidities, short ADL scale, premorbid IADLs and significant variable from unadjusted model.

**Data are presented as** odds ratio (95% confidence interval).

**Abbreviations:** ADL, activities of daily living; IADL, instrumental ADL; OR, odds ratio; CI, confidence interval.

Factors associated with polypharmacy {#sec020}
------------------------------------

The results of the multivariate logistic regression analyses for independent risk factors of polypharmacy are presented in [Table 7](#pone.0236830.t007){ref-type="table"}. The findings revealed that the presence of the diagnosis of gastroesophageal reflux disease (GERD) (OR = 6.03 \[1.64--22.09\]) and that of DDI (OR = 34.16 \[9.59--121.69\]) were associated with increased polypharmacy. Moreover, a greater number of prescribed medications for constipation, mineral supplements, antithrombotic agents, diuretics, agents acting on the renin-angiotensin system, lipid modifying agents, antibacterial drugs, analgesics and psycholeptics were strong associated risk factors of polypharmacy (P\<0.001).

10.1371/journal.pone.0236830.t007

###### Logistic regression model of factors associated with exposure to each criteria of PP, PIM and DDI.
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                                                      Polypharmacy                                                     PIM                                                           DDI
  --------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------- -----------------------------------------------------------
  **Patient characteristics**                                                                                                                                                        
  Number of comorbidities                                                                                                                                                            1.24 (1.03--1.48)[\*](#t007fn002){ref-type="table-fn"}
  History of GERD                                     6.03 (1.64--22.09)[\*\*](#t007fn003){ref-type="table-fn"}                                                                      
  **Medications characteristics**                                                                                                                                                    
  Number of medications                               [-^b^](#t007fn004){ref-type="table-fn"}                                                                                        1.46 (1.17--1.82)[\*\*](#t007fn003){ref-type="table-fn"}
  A06 Drugs for constipation                          14.21 (4.16--48.60) [\*\*](#t007fn003){ref-type="table-fn"}                                                                    
  A11 Vitamins                                        3.73 (1.25--11.17)[\*](#t007fn002){ref-type="table-fn"}                                                                        
  A12 Mineral supplements                             10.82 (2.29--51.09) [\*\*](#t007fn003){ref-type="table-fn"}                                                                    
  B01 Antithrombotic agents                           5.15 (1.63--16.28) [\*\*](#t007fn003){ref-type="table-fn"}                                                                     
  C01 Cardiac therapy                                                                                                  3.47 (1.80--6.66)[\*\*](#t007fn003){ref-type="table-fn"}      
  C02 Antihypertensives                                                                                                6.24 (1.26--30.83) [\*](#t007fn002){ref-type="table-fn"}      
  C03 Diuretics                                       120.83 (8.70--1678.36) [\*\*](#t007fn003){ref-type="table-fn"}                                                                 12.72 (1.64--98.68)[\*](#t007fn002){ref-type="table-fn"}
  C08 Calcium channel blockers                        7.48 (1.42--39.45) [\*](#t007fn002){ref-type="table-fn"}                                                                       
  C09 Agent acting on the renin- angiotensin system   9.81 (2.80--34.37) [\*\*](#t007fn003){ref-type="table-fn"}                                                                     
  C10 Lipid modifying agents                          14.55 (3.29--64.16) [\*\*](#t007fn003){ref-type="table-fn"}                                                                    
  J01 Antibacterial drugs                             29.29 (4.79--178.80) [\*\*](#t007fn003){ref-type="table-fn"}                                                                   
  N02 Analgesics                                      10.13 (2.97--34.52) [\*\*](#t007fn003){ref-type="table-fn"}                                                                    
  N05 Psycholeptics                                   19.71 (4.88--79.64) [\*\*](#t007fn003){ref-type="table-fn"}      18.38 (9.73--34.73) [\*\*](#t007fn003){ref-type="table-fn"}   
  N06 Psychoanaleptics                                                                                                 2.26 (1.30--3.93) [\*\*](#t007fn003){ref-type="table-fn"}     6.14 (2.35--16.08)[\*\*](#t007fn003){ref-type="table-fn"}
  Presence of PP                                      [-^b^](#t007fn004){ref-type="table-fn"}                                                                                        3.04 (1.12--8.27)[\*](#t007fn002){ref-type="table-fn"}
  Presence of PIM                                     0.30 (0.09--1.01)                                                [-^b^](#t007fn004){ref-type="table-fn"}                       2.07 (1.07--4.00)[\*](#t007fn002){ref-type="table-fn"}
  Presence of DDI                                     34.16 (9.59--121.69) [\*\*](#t007fn003){ref-type="table-fn"}     1.97 (1.08--3.62)[\*](#t007fn002){ref-type="table-fn"}        [-^b^](#t007fn004){ref-type="table-fn"}

^a^ Adjusted for age, sex, number of comorbidities, short ADL scale, premorbid IADLs and significant variable from unadjusted model

\* *P*\<0.05

\*\**P*\<0.01

\-^b^ Not include in adjusted analyses.

**Data are presented as** odds ratio (95% confidence interval).

**Abbreviations:** GERD, gastroesophageal reflux disease; PP, polypharmacy; PIM, potentially inappropriate medication; DDI, drug-drug interaction; OR, odds ratio; CI, confidence interval.

Factors associated with inappropriate medication use {#sec021}
----------------------------------------------------

The adjusted logistic regression analyses presented a greater risk of PIM which substantially increased with the condition of higher medication use in cardiac therapy (OR = 3.47 \[1.80--6.66\]), antihypertensives (OR = 6.24 \[1.26--30.83\]), psycholeptics (OR = 18.38 \[9.73--34.73\]) and psychoanaleptics (OR = 2.26 \[1.30--3.93\]), as presented in [Table 7](#pone.0236830.t007){ref-type="table"}. Furthermore, the occurrence of DDI was associated with PIM (OR = 1.97 \[1.08--3.62\]).

Factors associated with drug-drug interactions {#sec022}
----------------------------------------------

According to multivariate logistic regression analyses, associated independent risk factors of greater DDI were a higher number of comorbidities (OR = 1.24 \[1.03--1.48\]) and prescribed medications (OR = 1.46 \[1.17--1.82\]) as well as the presence of polypharmacy (OR = 3.04 \[1.12--8.27\]) and PIM (OR = 2.07 \[1.07--4.00\]). The prescriptions of diuretics (OR = 12.72 \[1.64--98.68\]) and psychoanaleptics (OR = 6.14 \[2.35--16.08\]) marginally increased the prevalence of DDI, as presented in [Table 7](#pone.0236830.t007){ref-type="table"}.

Discussion {#sec023}
==========

The current study has reported the risk factors associated with the exposure to three criteria or triad combination of PP, PIM and DDI and has explored the prevalence and characteristics of PP, PIM and DDI among the older people living with dementia admitted to an acute care setting during the period from 2006 to 2016. The prevalence of dementia in hospitalized elderly patients aged 65 and over was 13.9%, similar to the results of previous studies \[[@pone.0236830.ref074],[@pone.0236830.ref075]\]. With regard to primary diagnosis, consistent with the study of Toot et al and Andrieu et al, patients having behavioural and psychological symptoms of dementia (BPSD) are related to an increased risk of hospitalization \[[@pone.0236830.ref076],[@pone.0236830.ref077]\] as a result of caregivers' stress and burdens \[[@pone.0236830.ref078],[@pone.0236830.ref079]\]. In addition, falls and urinary tract infection are also common reasons for admission of people living with dementia, which is in line with previous studies \[[@pone.0236830.ref017],[@pone.0236830.ref079]--[@pone.0236830.ref088]\]. However, falls and urinary tract infection could have been prevented in this geriatric population. Amongst patients diagnosed with dementia, a higher use of indwelling catheters, dehydration, poor hygiene and urinary incontinence may be associated with an increased risk of urinary tract infection (UTI) \[[@pone.0236830.ref089]--[@pone.0236830.ref092]\]. Furthermore, in terms of neuropsychiatric treatment, sedatives or antipsychotics are widely prescribed, which may exacerbate urinary retention and reduce the patient's activity, leading to worsening UTI. Falls are common issues in these patients owing to having impaired visuospatial and executive functions as well as developing negative health outcomes from some medications to maintain cognitive functions and behavioral symptoms \[[@pone.0236830.ref093]\]. The most common co-morbidities are hypertension, followed by infection and coronary artery disease. The results of current study are similar to common combinations of chronic diseases found in the previous studies \[[@pone.0236830.ref094]--[@pone.0236830.ref097]\]. The most common pre-existing comorbidities with dementia such as hypertension and cardiovascular diseases could be explained that they are the predictors of the risk of dementia \[[@pone.0236830.ref095],[@pone.0236830.ref096],[@pone.0236830.ref098]\]. Compared to the non-triad combination group, the number of patients having diabetes mellitus, coronary artery disease and atrial fibrillation in the triad combination were substantially higher. Due to management, most patients with these chronic diseases were treated with multiple medications and with narrow therapeutic medications such as digoxin and warfarin, leading to an increased risk of the exposure to three criteria of PP, PIM and DDI \[[@pone.0236830.ref098]\].

The most frequently prescribed medication categories were antithrombotic agents and agents acting on the renin-angiotensin system which were prescribed for treatment of common chronic diseases such as hypertension and coronary artery diseases \[[@pone.0236830.ref099]\]. Furthermore, antithrombotic agents were widely prescribed for patients with hip fractures to prevent venous thromboembolism \[[@pone.0236830.ref054]\]. Comparing with non-triad combination group, the number of medications use in cardiac therapy, diuretics, psycholeptics and psychoanaleptics in triad combination group were substantially higher.

As would be expected, hospitalized older patients with dementia are prone to be prescribed five or more medications daily \[[@pone.0236830.ref041],[@pone.0236830.ref100]\], which are associated with higher co-morbidities and greater demented-related complications \[[@pone.0236830.ref033],[@pone.0236830.ref040]\]. In accordance to the study of Brunet et al and Von-Ranteln Kruse et al, between 82--98% of hospitalized older people living with dementia experienced polypharmacy \[[@pone.0236830.ref055],[@pone.0236830.ref056]\]. With regard to factors associated with polypharmacy, a higher number of prescribed medication in cardiac therapy, psycholeptics and psychoanaleptics were revealed. The findings from previous studies contribute to a growing body of evidence which demonstrates the presence of drug interactions associated with a higher risk of polypharmacy \[[@pone.0236830.ref101]--[@pone.0236830.ref103]\]. According to Park H-Y el al's study \[[@pone.0236830.ref104]\] polypharmacy is associated with the increase of comorbidities, which was not seen in our study.

In the case of inappropriate medication use, more than half of this geriatric population were more likely to be exposed to at least 1 PIM. This prevalence was higher than the results of previous studies \[[@pone.0236830.ref057],[@pone.0236830.ref105],[@pone.0236830.ref106]\]. However, the variability in prevalence of PIM depends on the population characteristics, healthcare settings and the PIMs lists used such as the Beer Criteria, the STOPP/START criteria, PRISCUS list and Laroche list \[[@pone.0236830.ref071],[@pone.0236830.ref107]--[@pone.0236830.ref109]\]. Regarding characteristics of PIMs according to the 2019 Beers criteria, the most common prescribed PIM classifications are cardiovascular system medications including cardiac therapy (antiarrhythmic agents) and central nervous system medications including psycholeptics and psychoanaleptics. These findings can explain why using of cardiac therapy, psycholeptics and psychoanaleptics are strong predictors of the occurrence of PIM. According to the 2019 Beers criteria, antipsychotics and benzodiazepines are considered common prescribed PIMs which may result in worsening of cognitive function and detrimental health consequences \[[@pone.0236830.ref071],[@pone.0236830.ref110]--[@pone.0236830.ref116]\]. Furthermore, antipsychotics are known as an increased risk of cardiovascular events (stroke and heart arrhythmia) and mortality \[[@pone.0236830.ref117]--[@pone.0236830.ref120]\] whereas benzodiazepines are labeled as the predictor of falls and fractures \[[@pone.0236830.ref121]\]. However, these PIMs could have been prevented if medication prescribing is carefully balanced between risks and benefits and is avoided for unsuitable patients. Although some dispensed medications such as antipsychotics and benzodiazepines could relieve BPSD, these medications should not be used as the first line treatment \[[@pone.0236830.ref114]\]. Therefore, precipitating causes should be managed and non-pharmacological treatment should be attempted before the initiation of antipsychotics \[[@pone.0236830.ref122],[@pone.0236830.ref123]\]. In contrast to previous studies \[[@pone.0236830.ref039],[@pone.0236830.ref124]--[@pone.0236830.ref126]\], PP and number of medications were not linked to the use of PIMs in this study. In dementia, common risk factors of PIMs are the use of medications to relieve BPSD such as psycholeptics and psychoanaleptics. Unlike our results, other studies \[[@pone.0236830.ref039],[@pone.0236830.ref127]\] have shown the associations of some medical conditions, such as urinary incontinence and osteoarthritis, with the use of PIMs.

The prevalence of DDI in this geriatric population with dementia in acute care setting was substantially higher than those prevalence in a previous study \[[@pone.0236830.ref060]\]. In this study, more than one third of elderly patients with dementia were exposed to major potential DDI, which is in line with Bogetti-Salazar 's study \[[@pone.0236830.ref128]\]. The most common potential DDI was the combination of heparin with aspirin which are prescribed to treat common comorbidities such as cardiovascular diseases. This common drug combination, in the study could be prescribed to prevent venous thromboembolism as complication of falls and fractures. This study demonstrates that the more prescribed medications patients take, the greater risks of DDIs they experience \[[@pone.0236830.ref060],[@pone.0236830.ref101],[@pone.0236830.ref128]\]. Furthermore, taking of PIMs and PP poses a significant risk of drug interactions \[[@pone.0236830.ref101],[@pone.0236830.ref129]\]. Additionally, specific medication classifications including psychoanaleptics (antidepressants and anti-dementia drugs) and diuretic are associated with a higher risk of DDI due to age-related pharmacokinetic and pharmacodynamic changes \[[@pone.0236830.ref060],[@pone.0236830.ref128],[@pone.0236830.ref130],[@pone.0236830.ref131]\]. However, no relationship was found between DDI and any specific medical condition factor, sex, age, activity of daily living \[[@pone.0236830.ref060],[@pone.0236830.ref128]\].

In terms of exposure to triad combination, older patients diagnosed with dementia are prone to triad combination of PP, PIM and DDI. In the context of predictors of triad combination, older patients with dementia having atrial fibrillation were found to be more likely to be exposed to triad combination of PP, PIM and DDIs as compared to those without atrial fibrillation. In treatment of atrial fibrillation and prophylaxis complications, many types of medications such as antiarrhythmic drugs and antithrombotic agents are prescribed as a combination of drugs of choice. These medications have significant narrow therapeutic index and dose-response variability, which may contribute to increased risk of PIM and DDI \[[@pone.0236830.ref132]\]. Additionally, an increased use of cardiac therapy, psychoanaleptics and psycholeptics were important risk factors of the exposure to triad combination of PP, PIM and DDI.

Medication management should vary based on individuals and prescribers should carefully consider patients' preferences for treatment as well as taking into account the risks and benefits of medication prescribing. Moreover, raising practitioners' awareness regarding careful medication use is essential to avoid undesirable drug problems such as PIMs and DDIs, the great proportion of which could be prevented. Therefore, strategies of comprehensive medication reviews and medication reconciliation by physicians and pharmacists should be initiated to optimize medication prescribing for hospitalized elderly patients with dementia in order to limit the occurrence of PP, PIM and DDI.

The strengths and limitations {#sec024}
-----------------------------

To our knowledge, this is the first study to explore risk factors associated with the exposure to the triad combination of PP, PIM and DDI and to evaluate the prevalence and characteristics of PP, PIM and DDI among older patients with dementia in an acute care setting during a ten-year period. Furthermore, a standardized interRAI Acute Care (AC) assessment tool was used to gather clinical information, social attributes and medication prescribing profiles of the geriatric population with dementia. Trained nurse assessors gathered all comprehensive health information data and conducted many clinical assessments for dementia to refer to interRAI acute care (AC) databases, as standard assessment database for acute care setting. The participants were determined by using a combination of medical records with standard cognitive testing including CPS scores ranging from 2 to 4 in order to support accuracy in dementia diagnosis.

Several limitations of this study have to be taken into consideration. First, this study was conducted only in older patients with dementia referred for specialist geriatric consultation in a single acute care setting; therefore, the findings may not be applicable to older persons admitted to other facilities or who are not diagnosed with dementia. Patients are generally referred for geriatric assessment for complex care needs and multimorbidity as well as decisions around discharge to residential aged care facilities, admission to transition care programs, and potential for rehabilitation. Not all patients with dementia are referred for specialist consultation and so the number enrolled in this study is likely to be an underestimation of the number of older patients with dementia admitted to hospital. Second, the number of older patients with dementia may be underestimated due to under-diagnosis before admission \[[@pone.0236830.ref012],[@pone.0236830.ref017],[@pone.0236830.ref020],[@pone.0236830.ref021]\]. Third, the identification of dementia subtypes may present differences in the results, but dementia was not classified following etiologies in this study. Fourth, the absence of detailed duration and indication of medication prescribing during admission may result in underestimation of PIMs. Fifth, clinical relevant outcomes due to drug interactions were not taken into account. Furthermore, all drug interactions were considered only by single pairwise of drug combination, but interactions from three drug combination or more were not accounted for. Finally, this study did not address other common DRPs among the elderly with dementia, such as ADRs \[[@pone.0236830.ref044]\].

Conclusion {#sec025}
==========

The exposure to triad combination of PP, PIM and DDI are common among people with dementia as a result of their vulnerable conditions and the greater risks of adverse events from medications use. This study identified the use of cardiac therapy, psycholeptics and psychoanaleptics as predictors of exposure to PP, PIM and DDI. Therefore, use of these medications should be carefully considered and closely monitored. Furthermore, comprehensive medication reviews to optimize medication prescribing should be initiated and continually implemented for this vulnerable population.
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